On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places Ono in direct competition with another Japanese pharmaceutical company, Daiichi Sankyo, in the TGCT...
Hence then, the article about ono s romvimza approval shakes up tenosynovial giant cell tumors market challenging daiichi sankyo s turalio dominance delveinsight was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance .. DelveInsight )
Also on site :
- One person in critical condition following two-vehicle collision on SR-126 at Boosey Road
- Supermarket timings for Boxing Day and New Year revealed for Asda, Tesco, Sainsbury’s, Aldi, Lidl and more
- Trump rants about Epstein in Christmas Day post claiming he dropped ties with sex offender ‘long before it became fashionable’